Wegovy, Ozempic exclusivity challenges denied by US patent appeal board
The US Patent and Trademark Office’s Patent Trial and Appeal Board has declined to review two patent challenges around Novo Nordisk’s semaglutide brought by generics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
